By Puyaan Singh (Reuters) - The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Centers for Medicare and Medicaid Services said it would not cover the medications under Medicare’s Part D coverage.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...

Popular weight loss drugs may do more than curb appetite — they may also help reduce the risk of dementia, according to new research.

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...